Emd serono pipeline. Merck holds the global rights to the Merck name and brand.

Emd serono pipeline Operating as EMD Serono in the US and Canada, the company is advancing several promising cancer treatments with the potential to greatly impact patient outcomes. healthcare business — set a goal to double R&D productivity in oncology, neurology and immunology, aiming to launch a new product or in a new indication about every one-and-a-half years. Nov 21, 2022 · Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its Healthcare business as EMD Serono in the US and Canada, today shared updates on the company’s healthcare research and development strategy, aimed at doubling R&D productivity. We focus on four innovation clusters: Oncogenic Signaling DNA Damage Response (DDR) Antibody-Drug Conjugates (ADCs) Tumor Immunology As Jun 3, 2022 · EMD Serono Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways An update on the progress of the company’s innovative oncology development pipeline focused on DNA damage biology. EMD Serono is a specialty innovator that helps create, improve and prolong lives for people living with infertility, multiple sclerosis and cancer. About EMD Serono, Inc. Our GONAL-f ® (follitropin alfa injection) treatment is the most prescribed r May 21, 2025 · The company announced positive data on enpatoran demonstrating reduction in disease activity in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) with active lupus rash. Our pipeline is strong, we have multiple clinical development programs underway with potential first-in-class and / or best-in-class assets like enpatoran, oral cladribine for Myasthenia gravis, next-generation ADCs and our DDR portfolio. Merck holds the global rights to the Merck name and brand. May 7, 2025 · Explore EMD Serono Research & Development Institute, Inc. The Marketing Authorization for Euthyrox ® has been transferred to EMD Serono, Inc. For over 75 years, we’ve been supporting fertility treatment needs with medications for stimulation, control, and ovulation—all designed to help increase the chances of OI and ART success 1. We’re focused on discovering new solutions for today and the future. May 25, 2023 · EMD Serono Highlights Commitment to Improving Cancer Outcomes at ASCO 2023 43 abstracts covering several modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago. is September 2026. Merck KGaA, Darmstadt, Germany, a leading science and technology company that operates its Healthcare business as EMD Serono in the US and Canada, today shar May 13, 2020 · EMD Serono announced data for its investigational agents and investigational uses of marketed medicines to be presented at the American Society of Clinical Oncology (ASCO) ASCO20 Virtual Scientific Program. Aug 15, 2025 · Merck KGaA ventures into new territory in the US How the president of EMD Serono, Merck KGaA, Darmstadt, Germany’s U. Oct 30, 2023 · Merck KGaA, Darmstadt, Germany, Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate EMD Serono is working to develop solutions that could impact multiple immunological & neurological conditions, including multiple sclerosis. We would like to show you a description here but the site won’t allow us. Sep 14, 2020 · EMD Serono Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020 New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO®* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer The interactive pipeline of Merck shows what the company is currently working on and can be filtered based on different factors. EMD Serono is headquartered in Mississauga, Ontario. Jun 3, 2024 · The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics. Nov 27, 2023 · One year ago, EMD Serono — Germany-based Merck KGaA’s U. and Canada, today announced the appointment of Miguel Fernández Alcalde as President of EMD Serono. Jun 13, 2024 · Merck KGaA, a prominent science and technology company headquartered in Darmstadt, Germany, has shared significant updates on its oncology pipeline and its comprehensive research and development initiatives. Jun 3, 2024 · Merck KGaA, Darmstadt, Germany, a leading science and technology company that operates its Healthcare business as EMD Serono in the US and Canada, today shared updates on the company’s oncology pipeline and focused approach to the research and development of potential new medicines designed to improve the futures of people with cancer. Apr 12, 2021 · Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by EMD Serono As a science-driven organization, we aim to deliver a transformative pipeline that makes a real difference for patients and carers, with a strong focus on helping to create, improve and prolong lives. The Project is a comprehensive, multi-phase, global consensus initiative aimed not only at identifying and prioritizing the top challenges in the lupus field, but also creating . Press Releases 1 2 3 EMD Serono is a specialty innovator that helps create, improve and prolong lives for people living with infertility, multiple sclerosis and cancer. Patient Resources CoverOne ®: Patient access and reimbursement support EMD Serono Clinical Trials Nov 22, 2021 · Merck KGaA, Darmstadt, Germany Highlights Novel Mechanisms with the Potential to Transform Standards of Care in Several Cancers, MS, and Lupus Merck KGaA, Darmstadt, Germany, today provided an overview of its innovative pipeline with a focus on five mid- to late-stage assets with first-in-class and/or best-in-class potential at its R&D Update Call. Potential shortages may occur. Achieving that goal would require the company to shift its strategy from developing only drugs in its own internal pipeline to also Jun 3, 2024 · Darmstadt, Germany, June 3, 2024 – Merck KGaA, Darmstadt, Germany, a leading science and technology company that operates its Healthcare business as EMD Serono in the US and Canada, today shared updates on the company’s oncology pipeline and focused approach to the research and development of potential new medicines designed to improve the EMD Serono has a proven legacy of delivering meaningful therapies for people living with difficult-to-treat diseases. Nov 22, 2021 · The founding family remains the majority owner of the publicly listed company. All are selective, clearly differentiated and have the potential to be best-in-class. The aim of this investigational drug is to control tumor growth by restoring and enhancing anti-tumor immune responses. EMD Serono is the biopharmaceutical business of Merck KGaA, Darmstadt, Germany. Jun 12, 2025 · EMD Serono Presents Results on Efficacy and Safety of Enpatoran in SLE at EULAR 2025 Company presents phase 2 data of enpatoran in systemic lupus erythematosus, highlighting improved efficacy in patients with active skin manifestations EMD Serono has deep expertise in neurology, fertility and endocrinology, and a pipeline in neurology, oncology, immunology and immuno-oncology. with its drug pipeline, therapeutic area, technology platform, 147 clinical trials, 341 news, and 242 literature, Disease Domain EMD Serono Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO The company today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Our strong heritage in fertility has helped us build a portfolio prescribed by fertility professionals all over the world. M7824 is a potentially first-in-class bi-functional immunotherapy in clinical trials designed to simultaneously block two immuno-inhibitory pathways that are commonly used by cancer cells to evade the immune system. (a business of Merck KGaA, Darmstadt, Germany) and through additional support by GlaxoSmithKline. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. , effective April 2025. May 7, 2025 · Explore EMD Serono, Inc. All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. A Strong Pipeline Our global pipeline is the strongest it has ever been, with more than 20 projects in clinical development focused on potential new oncology and immune-oncology medicines in more than 15 difficult-to-treat tumor types, as well as investigational treatments for psoriasis, lupus, multiple sclerosis and other autoimmune diseases. We have a proud legacy of turning breakthrough science into medicines and vaccines that save and improve lives around the world. The last expiration date of the finished product currently on the market in the U. This year, the company At EMD Serono, we act boldly, empowered by cutting-edge science that delivers valuable medicines, drug-delivery devices and support services for patients with difficult-to-treat diseases. with its drug pipeline, therapeutic area, technology platform, 86 clinical trials, 1 news, and 382 literature, Disease Domain:Neoplasms, Endocrinology and Metabolic Disease, Nervous System Diseases, Immune System Diseases, Infectious Diseases, Hemic and Lymphatic Diseases, Technology Platform:Small molecule drug, Monoclonal antibody May 21, 2025 · In addition to EMD Serono’s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and generalized myasthenia gravis (gMG). We’re grateful to the thousands of volunteers who participate in our clinical trials — making this all possible. EMD Serono has a proven legacy of delivering meaningful therapies for people living with difficult-to-treat diseases. Explore our solutions. Jun 10, 2025 · Press Releases 10 Dec 2024 EMD Serono Appoints Miguel Fernández Alcalde to Lead North American Healthcare Business EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the U. Ltd, Shanghai, China, for pimicotinib (ABSK021), which is currently being evaluated in a Phase III study for the treatment of tenosynovial giant cell tumor (TGCT). S. Jun 12, 2025 · EMD Serono today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an investigational, oral, novel TLR7/8 inhibitor in systemic lupus erythematosus (SLE). Together we’re working to build up our oncology pipeline with an immuno-oncology program covering 15 difficult-to-treat tumour types. Our oncology pipeline holds promise in the near term through our later-stage priority programs, and our early pipeline includes several potentially groundbreaking modalities. The ALPHA Project was launched in partnership with founding partner EMD Serono Research & Development Institute, Inc. May 23, 2024 · EMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024 Data from company- and investigator-sponsored studies include 31 accepted abstracts across more than 10 tumor types, including seven oral presentations, highlighting the company’s innovative oncology pipeline. As our work continues, we hope to uncover potential new medicines that can help meet patients’ many unmet medical needs. arm, is leading the charge to “double down” on new innovation. Nov 3, 2025 · A quarterly overview of Merck’s clinical trials pipeline. This table provides Dec 4, 2023 · Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a license agreement with Abbisko Therapeutics Co. The interactive pipeline of Merck KGaA, Darmstadt, Germany, shows what the company is currently working on and can be filtered based on different factors. fi7wf 9sq c2hap ksu 5sv2 lfq o1dge9ty hj3kgz iuzmy 48zxyu